ImmuPharma plc (LON:IMM – Get Free Report)’s stock price rose 56% during mid-day trading on Monday . The company traded as high as GBX 7.14 ($0.09) and last traded at GBX 6.14 ($0.08). Approximately 39,645,953 shares were traded during trading, an increase of 91% from the average daily volume of 20,792,326 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Performance
The firm has a market cap of £19.64 million, a P/E ratio of -471.50 and a beta of 1.53. The business has a 50-day simple moving average of GBX 1.92 and a 200 day simple moving average of GBX 1.78.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- What is the Nasdaq? Complete Overview with History
- 3 Trucking Stocks Leading the Way in Market Momentum
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Stocks to Gain From Trump’s Family Caregiver Tax Credits
- 3 Monster Growth Stocks to Buy Now
- Charging Forward: 2 US Battery Stocks to Electrify Your Portfolio
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
